134 related articles for article (PubMed ID: 38092107)
1. Rational engineering and insight for a L-glutaminase activity reduced type II L-asparaginase from Bacillus licheniformis and its antileukemic activity in vitro.
Zhou Y; Shen J; Chi H; Zhu X; Lu Z; Lu F; Zhu P
Int J Biol Macromol; 2024 Feb; 257(Pt 2):128690. PubMed ID: 38092107
[TBL] [Abstract][Full Text] [Related]
2. Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies.
Ardalan N; Mirzaie S; Sepahi AA; Khavari-Nejad RA
Med Hypotheses; 2018 Mar; 112():7-17. PubMed ID: 29447943
[TBL] [Abstract][Full Text] [Related]
3. Enhancing the Catalytic Activity of Type II L-Asparaginase from
Zhou Y; Jiao L; Shen J; Chi H; Lu Z; Liu H; Lu F; Zhu P
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077061
[TBL] [Abstract][Full Text] [Related]
4. Development of Escherichia coli asparaginase II for the Treatment of Acute Lymphocytic Leukemia: In Silico Reduction of asparaginase II Side Effects by a Novel Mutant (V27F).
Ardalan N; Akhavan Sepahi A; Khavari-Nejad RA
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1137-1147. PubMed ID: 33906306
[TBL] [Abstract][Full Text] [Related]
5. Structures of l-asparaginase from
Ran T; Jiao L; Wang W; Chen J; Chi H; Lu Z; Zhang C; Xu D; Lu F
J Agric Food Chem; 2021 Jan; 69(1):223-231. PubMed ID: 33371681
[TBL] [Abstract][Full Text] [Related]
6. Enhanced catalysis of L-asparaginase from Bacillus licheniformis by a rational redesign.
Sudhir AP; Agarwaal VV; Dave BR; Patel DH; Subramanian RB
Enzyme Microb Technol; 2016 May; 86():1-6. PubMed ID: 26992786
[TBL] [Abstract][Full Text] [Related]
7. A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
Sugimoto K; Suzuki HI; Fujimura T; Ono A; Kaga N; Isobe Y; Sasaki M; Taka H; Miyazono K; Komatsu N
Cancer Sci; 2015 Nov; 106(11):1534-43. PubMed ID: 26331698
[TBL] [Abstract][Full Text] [Related]
8. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Chan WK; Horvath TD; Tan L; Link T; Harutyunyan KG; Pontikos MA; Anishkin A; Du D; Martin LA; Yin E; Rempe SB; Sukharev S; Konopleva M; Weinstein JN; Lorenzi PL
Mol Cancer Ther; 2019 Sep; 18(9):1587-1592. PubMed ID: 31209181
[TBL] [Abstract][Full Text] [Related]
9. A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias
Nguyen HA; Su Y; Zhang JY; Antanasijevic A; Caffrey M; Schalk AM; Liu L; Rondelli D; Oh A; Mahmud DL; Bosland MC; Kajdacsy-Balla A; Peirs S; Lammens T; Mondelaers V; De Moerloose B; Goossens S; Schlicht MJ; Kabirov KK; Lyubimov AV; Merrill BJ; Saunthararajah Y; Van Vlierberghe P; Lavie A
Cancer Res; 2018 Mar; 78(6):1549-1560. PubMed ID: 29343523
[TBL] [Abstract][Full Text] [Related]
10. The differential ability of asparagine and glutamine in promoting the closed/active enzyme conformation rationalizes the Wolinella succinogenes L-asparaginase substrate specificity.
Nguyen HA; Durden DL; Lavie A
Sci Rep; 2017 Jan; 7():41643. PubMed ID: 28139703
[TBL] [Abstract][Full Text] [Related]
11. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).
Panosyan EH; Grigoryan RS; Avramis IA; Seibel NL; Gaynon PS; Siegel SE; Fingert HJ; Avramis VI
Anticancer Res; 2004; 24(2C):1121-5. PubMed ID: 15154634
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Thermostability and Molecular Insights for l-Asparaginase from
Chi H; Wang Y; Xia B; Zhou Y; Lu Z; Lu F; Zhu P
J Agric Food Chem; 2022 Nov; 70(45):14499-14509. PubMed ID: 36341695
[TBL] [Abstract][Full Text] [Related]
13. Recombinant production and characterization of L-glutaminase (glsA) as a promiscuity therapeutic enzyme.
Simay S; Akbarzadeh-Khiavi M; Pourseif MM; Barar J; Safary A; Omidi Y
Appl Microbiol Biotechnol; 2022 Sep; 106(17):5511-5524. PubMed ID: 35876873
[TBL] [Abstract][Full Text] [Related]
14. Engineering of Helicobacter pylori L-asparaginase: characterization of two functionally distinct groups of mutants.
Maggi M; Chiarelli LR; Valentini G; Scotti C
PLoS One; 2015; 10(2):e0117025. PubMed ID: 25664771
[TBL] [Abstract][Full Text] [Related]
15. Purification and characterization of a novel and robust L-asparaginase having low-glutaminase activity from Bacillus licheniformis: in vitro evaluation of anti-cancerous properties.
Mahajan RV; Kumar V; Rajendran V; Saran S; Ghosh PC; Saxena RK
PLoS One; 2014; 9(6):e99037. PubMed ID: 24905227
[TBL] [Abstract][Full Text] [Related]
16. Aliivibrio fischeri L-Asparaginase production by engineered Bacillus subtilis: a potential new biopharmaceutical.
Bento HBS; Paiva GB; Almeida MR; Silva CG; Carvalho PJ; Tavares APM; Pedrolli DB; Santos-Ebinuma VC
Bioprocess Biosyst Eng; 2022 Oct; 45(10):1635-1644. PubMed ID: 35974197
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of active site mutant of antileukemic L-asparaginase reveals conserved zinc-binding site.
Borek D; Kozak M; Pei J; Jaskolski M
FEBS J; 2014 Sep; 281(18):4097-111. PubMed ID: 25040257
[TBL] [Abstract][Full Text] [Related]
18. Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines.
Parmentier JH; Maggi M; Tarasco E; Scotti C; Avramis VI; Mittelman SD
Leuk Res; 2015 Jul; 39(7):757-62. PubMed ID: 25941002
[TBL] [Abstract][Full Text] [Related]
19. Homology modeling and molecular docking studies to decrease glutamine affinity of Yarrowia lipolytica L-asparaginase.
Darvishi F; Beiranvand E; Kalhor H; Shahbazi B; Mafakher L
Int J Biol Macromol; 2024 Apr; 263(Pt 2):130312. PubMed ID: 38403216
[TBL] [Abstract][Full Text] [Related]
20. In silico engineering of L-asparaginase to have reduced glutaminase side activity for effective treatment of acute lymphoblastic leukemia.
Ln R; Doble M; Rekha VP; Pulicherla KK
J Pediatr Hematol Oncol; 2011 Dec; 33(8):617-21. PubMed ID: 22042278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
